Article Data

  • Views 545
  • Dowloads 108

Original Research

Open Access

Outcomes of patients with intermediate risk early stage cervical adenocarcinoma – a single institution experience

  • J. Jonska-Gmyrek1,2,*,
  • A. Zolciak-Siwinska3
  • B. Kotowicz4
  • L. Gmyrek5
  • M. Fuksiewicz4
  • W. Michalski1
  • J. Leibschang5
  • M. Kowalska4

1Department of Urooncology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

2Department of Radiation Oncology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

3 Department of Brachytherapy, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

4Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

5Department of Gynecological Oncology, Holy Family Hospital, Warsaw, Poland

DOI: 10.12892/ejgo4191.2018 Vol.39,Issue 4,August 2018 pp.600-603

Published: 10 August 2018

*Corresponding Author(s): J. Jonska-Gmyrek E-mail: jonska@wp.pl

Abstract

Purpose of investigation: To assess the treatment efficacy in FIGO Stage I AC (adenocarcinoma, AC) patients with a special focus on treatment failure. Materials and Methods: Among 93 patients with AC of the uterine cervix, 33 patients with FIGO Stage I were treated with radical hysterectomy (RH) and adjuvant treatment, according to the presence of risk factors in the histopathology protocol. Results: The median follow-up after treatment was 61 (range: 7-96) months. Recurrence developed in six (18%) of the 33 patients; two died of cervical cancer. In three cases (9%), recurrence was outside the pelvis and in three (9%) loco-regional recurrence was confirmed. All recurrences occurred in the intermediate and high-risk group. Conclusion: Outcomes of patients with intermediate risk factors in early cervical AC treated with surgery and adjuvant radiotherapy (RT) are unsatisfactory. The studies confirming how patients with intermediate risk factors may benefit from adjuvant chemoradiotherapy (CRT) seem to be necessary.

Keywords

Adenocarcinoma; Cervical cancer; Radiochemotherapy; Surgery; Treatment outcome.

Cite and Share

J. Jonska-Gmyrek,A. Zolciak-Siwinska,B. Kotowicz,L. Gmyrek,M. Fuksiewicz,W. Michalski,J. Leibschang,M. Kowalska. Outcomes of patients with intermediate risk early stage cervical adenocarcinoma – a single institution experience. European Journal of Gynaecological Oncology. 2018. 39(4);600-603.

References

[1] Wiebe E., Denny L., Thomas G.: “Cancer of the cervix uteri”. Int. J. Gynaecol. Obstet., 2012, 119, 100.

[2] Liu S., Semenciw R., MaoY.: “Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women”. CMAJ, 2001, 164, 1151.

[3] Liu S., Semenciw R., Probert A., Mao Y.: “Cervical cancer in Canada: changing patterns in incidence and mortality”. Int. J. Gynecol. Cancer, 2001, 11, 24.

[4] Sasieni P., Adams J.: “Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England”. Lancet, 2001, 12, 1490.

[5] Krane J.F., Granter S.R., Trask C.E., Hogan C.L., Lee K.R.: “Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases”. Cancer, 2001, 93, 8.

[6] Peters W.A 3rd., Liu P.Y., Barrett R.J 2nd., Stock R.J., Monk B.J., Berek J.S., et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J Clin Oncol., 2000, 18, 1606.

[7] Rotman M., Sedlis A., Piedmonte M.R., Bundy B., Lentz S.S., Muderspach L.I., Zaino R.,J.: “A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 169.

[8] Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., Zaino.: “A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy” A Gynecologic Oncology Group Study”. Gynecol Oncol., 1999, 73, 177.

[9] Kümmel S., Thomas A., Jeschke S., Hauschild M., Sehouli J., Lichtenegger W., Blohmer J.U.: “Postoperative therapy modalities for cervical carcinoma”. Anticancer Res., 2006, 26, 1707.

[10] Park J.Y., Kim D.Y., Kim J.H., Kim Y.M., Kim Y.T., Nam J.H.: “Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix”. Br. J. Cancer, 2010, 102, 1692.

[11] Huang Y.T., Wang C.C., Tsai C.S., Lai C.H., Chang T.C., Chou H.H., et al.: “Long-term outcome and prognostic factors for adenocarcinoma/ adenosquamous carcinoma of cervix after definitive radiotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 2011, 80, 429.

[12] Takeshima N., Utsugi K., Hasumi K., Takizawa K.: “Postoperative adjuvant chemotherapy for node-positive cervical adenocarcinoma”. Int J Gynecol Cancer. 2009., 19, 277.

[13] Micha J.P., Goldstein B.H., Rettenmaier M.A., Brown J.V 3rd., John C.R., Markman M.: “Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulkystage IB2 cervical carcinoma”. Int J Gynecol Cancer., 2006, 16, 1147.

[14] Huang Y.T, Wang C.C., Tsai C.S., Lai CH., Chang T.C., Chou H.H., et al.: “Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 2012, 84, 420.

[15] Eifel P.J., Burke T.W., Morris M., Smith T.L.: “Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma”. Gynecol. Oncol., 1995, 59, 38.

[16] Rosa D.D., Medeiros L.R., Edelweiss M.I., Pohlmann P.R., Stein A.T.: “Adjuvant platinum-based chemotherapy for early stage cervical cancer”. Cochrane Database Syst Rev., 2012, 13, CD005342.

[17] Demirci S., Ozsaran Z., Ozsaran A., Yavas F., Demircioglu B., Hanhan M., et al.: “Evaluation of treatment results and prognostic factors in early-stage cervical carcinoma patients treated with postoperative radiotherapy or radiochemotherapy”. Eur. J. Gynaecol. Oncol., 2012, 33, 62.

[18] Pu J., Qin S.S., Ding J.X, Zhang Y., Zhu W.G., Yu C.H., et al. “A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk earlystage cervical cancer after radical surgery”. J. Cancer Res. Clin. Oncol., 2013, 139, 703.

[19] Rotman M., Sedlis A., Piedmonte M.R., Bundy B., Lentz S.S., Muderspach., Zaino R.J.: “A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 169.

[20] Baalbergen A., Ewing-Graham P.C., Hop W.C., Struijk P., Helmerhorst T.J.: “Prognostic factors in adenocarcinoma of the uterine cervix”. Gynecol. Oncol., 2004, 92, 262.

[21] Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I, Chafe W.E., Suggs C.L 3rd, et al.: “Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma”. N. Engl. J. Med., 1999, 340, 1154.

[22] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al.: “Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer”. N. Engl. J. Med., 1999, 340, 1144.

[23] Serkies K., Jassem J.: “Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity”. Int J Radiat Oncol Biol Phys., 2004, 60, 814.

[24] Van de Putte G., Lie A.K., Vach W., Baekelandt M., Kristensen G.B.: “Risk grouping in stage IB squamous cell cervical carcinoma”. Gynecol Oncol., 2005, 99, 106.

[25] Gien L.T., Beauchemin M.C., Thomas G.: “Adenocarcinoma: a unique cervical cancer”. Gynecol Oncol., 2010, 116, 140.

[26] Jonska-Gmyrek J., Zolciak-Siwinska A., Gmyrek L.: “Can the histopathology influence the outcome of early–stage cervical cancer?” Eur. J. Gynaecol. Oncol., 2016, 2, 178.

[27] Lai C.H., Hsueh S., Hong J.H., Chang T.C., Tseng CJ., Chou H.H., et al.: “Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinoma in stage IB and II cervical cancer patients undergoing primary radical surgery?”. Int. J. Gynecol. Cancer, 1999, 9, 28.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top